Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.
Subscribe To Our Newsletter & Stay Updated
